Optimizing Post–CAR T Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience

Mazyar Shadman, MD, MPH and Sayeef Mirza, MD, MPH, FACP discuss how real-world data from over 1,500 patients demonstrates that CAR-T therapy toxicities like cytokine release syndrome and neurotoxicity occur predominantly within the first two weeks post-infusion, supporting the potential for reduced monitoring requirements and improved patient access to these life-saving treatments.